Janus Henderson Investors

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

Long-duration iron-air batteries designed to store electricity for multi-day grid needs.

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

Developing transformative, best-in-class neuropsychiatric therapies

Develops novel antibody treatments for immunological and inflammatory disorders

Develops medical devices for kidney stone treatment and removal

Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

Develops novel therapies to reduce the burden of neurodegenerative diseases

Developing a next-generation pertussis vaccine candidate BPZE1

Provides next-generation space and defense communications

Develops precision immunoregulatory medicines based on tissue Treg biology

Develops small molecule drugs for historically challenging drug targets

Develops bispecific antibody CLD-423 for inflammatory bowel disease

Develops medicines targeting historically undruggable protein targets in cancer